Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo
Pressmeddelanden • Sep 18, 2020 09:17 CEST
AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response following platinum-based chemotherapy.
Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
Pressmeddelanden • Sep 18, 2020 09:16 CEST
Updated results from the PACIFIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a sustained, clinically meaningful overall survival (OS) and progression-free survival (PFS) benefit in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) who had not progressed following concurrent chemoradiation therapy (CRT).
Pressmeddelanden • Sep 12, 2020 15:22 CEST
Clinical trials for the AstraZeneca Oxford coronavirus vaccine, AZD1222, have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so.
Pressmeddelanden • Sep 10, 2020 08:03 CEST
AstraZeneca today announced that it will be transferring the listing of its American Depositary Receipts (ADRs) and its US listed debt securities from the New York Stock Exchange (NYSE) to the Nasdaq Global Select Market (Nasdaq) and Nasdaq Bond Exchange respectively. The transfers will be effective after market close on Thursday 24 September 2020.
Fasenra met both co-primary endpoints of reduced nasal polyp size and blockage in the OSTRO Phase III trial for patients with chronic rhinosinusitis with nasal polyps
Pressmeddelanden • Sep 10, 2020 08:01 CEST
High-level results from the OSTRO Phase III trial showed AstraZeneca’s Fasenra (benralizumab) compared with placebo demonstrated a statistically significant improvement in the size of nasal polyps and in nasal blockage in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).
Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause
Pressmeddelanden • Sep 09, 2020 15:20 CEST
As part of the ongoing randomised, controlled clinical trials of the AstraZeneca Oxford coronavirus vaccine, AZD1222, a standard review process has been triggered, leading to the voluntary pause of vaccination across all trials to allow an independent committee to review the safety data of a single event of an unexplained illness that occurred in the UK Phase III trial.
AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020
Pressmeddelanden • Sep 08, 2020 08:02 CEST
AstraZeneca will present new developments in pursuit of its ambition to eliminate cancer as a cause of death at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, 19 to 21 September.
New analyses from Breztri Aerosphere Phase III ETHOS trial to be presented at the European Respiratory Society International Congress 2020
Pressmeddelanden • Sep 07, 2020 08:08 CEST
A post-hoc analysis of the Phase III ETHOS trial showed a consistent benefit of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate) in reducing the rate of moderate or severe chronic obstructive pulmonary disease (COPD) exacerbations across all seasons compared with Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to very severe disease.
Pressmeddelanden • Sep 01, 2020 08:06 CEST
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin.
Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
Pressmeddelanden • Aug 31, 2020 22:52 CEST
Trial enrolling up to 30,000 adults aged 18 years or over to assess safety, efficacy and immunogenicity of AZD1222 for the prevention of COVID-19 AZD1222 supported by safety and immunogenicity across all adult age groups
Pressmeddelanden • Aug 31, 2020 22:45 CEST
AstraZeneca is implementing a clinical development program that will enrol in excess of 50,000 volunteers, including 30,000 in the US, in Latin America, Asia, Europe, Russia and Africa that will provide data for ethnically diverse populations.
Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial
Pressmeddelanden • Aug 30, 2020 17:07 CEST
Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (CKD) Stages 2-4 and elevated urinary albumin excretion.
Pressmeddelanden • Aug 27, 2020 08:10 CEST
AstraZeneca will present the highly anticipated detailed results from the ground-breaking Phase III DAPA-CKD trial of Farxiga in chronic kidney disease (CKD) at ESC Congress 2020 – The Digital Experience. These results are among 20 abstracts being presented by AstraZeneca at ESC between 29 August to 1 September 2020 showcasing the breadth of its cardiovascular (CV), renal and metabolic portfolio.
Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19
Pressmeddelanden • Aug 25, 2020 15:01 CEST
The first participants have been dosed in a Phase I trial of AZD7442, a combination of two monoclonal antibodies (mAbs) in development for the prevention and treatment of COVID-19.
Pressmeddelanden • Aug 21, 2020 08:02 CEST
AstraZeneca’s Imfinzi (durvalumab) has been approved in Japan for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC), in combination with etoposide plus a choice of platinum chemotherapy (either carboplatin or cisplatin). SCLC is a highly aggressive, fast-growing form of lung cancer that typically recurs and progresses rapidly, despite initial response to chemotherapy.
Pressmeddelanden • Aug 18, 2020 08:03 CEST
AstraZeneca's Imfinzi (durvalumab) has received acceptance for its supplemental Biologics License Application (sBLA) and has also been granted Priority Review in the US for a new four-week, fixed-dose regimen for treatment in the approved indications of non-small cell lung cancer (NSCLC) and bladder cancer.
AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine
Pressmeddelanden • Aug 14, 2020 13:04 CEST
First European Commission COVID-19 vaccine agreement enables all EU member states to access the vaccine at no profit during the pandemic
Nirsevimab reduced respiratory syncytial virus infections and hospitalisations in preterm infants in Phase IIb trial
Pressmeddelanden • Jul 30, 2020 08:56 CEST
Nirsevimab showed a significant reduction in medically-attended lower respiratory tract infections (LRTI) and hospitalisations caused by respiratory syncytial virus (RSV) in healthy preterm infants in a positive Phase IIb trial published in the New England Journal of Medicine.
Tagrisso granted Breakthrough Therapy Designation in the US for the adjuvant treatment of patients with Stage IB-IIIA EGFR-mutated lung cancer
Pressmeddelanden • Jul 30, 2020 08:54 CEST
Designation based on unprecedented results from the Phase III ADAURA trial where Tagrisso reduced the risk of disease recurrence or death by c. 80%